Summary

for people ages 18 years and up (full criteria)
at UCLA UCSD
study started
estimated completion

Description

Summary

The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

Official Title

A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Keywords

Bladder Cancer Urothelial Carcinoma Metastatic Urothelial Carcinoma Renal Pelvis Carcinoma Ureter Carcinoma Urinary Bladder Carcinoma Urethra Carcinoma Muscle Invasive Bladder Cancer PARP inhibitor PARPi HRD ATLAS homologous recombination DNA repair LOH DNA defect DNA anomaly Rucaparib MIBC Carcinoma Urinary Bladder Neoplasms Carcinoma, Transitional Cell

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)
  • Received 1 or 2 prior treatment regimens for advanced or metastatic disease
  • Confirmed radiologic disease progression during or following recent treatment
  • Mandatory biopsy is required during screening
  • Measurable disease per RECIST v1.1
  • Adequate organ function
  • ECOG 0 or 1

You CAN'T join if...

  • Prior treatment with a PARP inhibitor
  • Symptomatic and/or untreated CNS metastases
  • Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib

Locations

  • University of California San Diego (UCSD), Moores Cancer Center
    La Jolla California 92093 United States
  • University of California, Los Angeles (UCLA)
    Los Angeles California 90095 United States
  • Saint John's Health Center - John Wayne Cancer Institute (JWCI)
    Santa Monica California 90404 United States
  • Universityof California, Irvine
    Orange California 92868 United States

Details

Status
currently not accepting new patients, but might later
Start Date
Completion Date
(estimated)
Sponsor
Clovis Oncology, Inc.
ID
NCT03397394
Phase
Phase 2
Study Type
Interventional
Last Updated